Find the next decision worth funding

Explore Opportunities

Most actionable first. Assess the next decision, not the size of the database.

877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.

How “most actionable” works

Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.

WATCH · WITHDRAWN

Isoniazid

Tuberculosis Infection

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Lack of Rifapentine

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Lack of Rifapentine

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-09. Registry source

WATCH · SUSPENDED

Isovorin

Metastatic Colorectal Cancer

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-11-01. Registry source

WATCH · TERMINATED

Ivabradine

Heart Failure

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Lack of patient enrollment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Lack of patient enrollment

Why stranded: Recruitment/execution failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-11. Registry source

WATCH · WITHDRAWN

IX001 TCR-T cells

Pancreatic Cancer, Colorectal Cancer

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Study was stopped Sponsor discretion. No patients were dosed.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Study was stopped Sponsor discretion. No patients were dosed.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-02. Registry source

WATCH · TERMINATED

JMT103

Hypercalcemia of Malignancy

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Due to a change in the company's research strategy

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Due to a change in the company's research strategy

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-18. Registry source

WATCH · TERMINATED

JS111(AP-L1898 Capsules)

Lung Cancer

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT The study was stopped because of a change in the study strategy

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

The study was stopped because of a change in the study strategy

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-10. Registry source

WATCH · WITHDRAWN

Kaletra (lopinavir/ritonavir)

HIV Infection, Hepatitis C

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2006-07-27. Registry source

WATCH · TERMINATED

Ketamine

Ketamine, Refractory Cancer Pain

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT The study was terminated early due to the principal investigator's transition to another institution.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

The study was terminated early due to the principal investigator's transition to another institution.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-18. Registry source

WATCH · TERMINATED

Kinerase Pro+Therapy Line day repair, serum, night repair

Skin Aging

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-12-24. Registry source

WATCH · TERMINATED

Kinerase Pro+Therapy Line Ultra rich day repair

Skin Aging

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-12-24. Registry source

WATCH · TERMINATED

L ARG

Intra Uterine Growth Retardation

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT terminated

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

terminated

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-10-26. Registry source

WATCH · TERMINATED

L-743,872

Candidiasis, Oral, HIV Infections

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2005-06-24. Registry source